I don't know much about spin-offs and what not but if all of ya'll are saying this will be beneficial to us then that makes me happy.

If you're talking about a license to grow, I don't see why we would need that to start R&D. If you're talking about a license to initiate R&D then that's a different story and I'd like to hear more news on that. It doesn't matter how much MJ we produce in the future, if MJ is not approved for specific patients or is used as a last resort treatment then the industry won't make much money. R&D is important because we'll eventually get to use MJ for clinical trials on humans and hopefully receive significant data on numerous test subjects so MJ use can become a 2nd or 1st line treatment.